Skip to main content

Patients as Research Partners

Integrated patient engagement model

CCTG uses an integrated patient engagement model that includes the patient voice in all aspects of cancer clinical trial development. A Patient Representative is not only involved in answering the scientific questions that clinical trials ask, they play an essential role on CCTG’s national disease site committee as participating members who contribute to the development and delivery of the cancer research questions. Patient Representatives ensure that patient centred outcomes included in CCTG cancer clinical trials.

A Current Oncology publication outlining the incorporation of patient engagement in the development of clinical trial at CCTG: Integrating Patient Centred Research in the Canadian Cancer Trials Group

Patient-oriented research refers to research that engages patients as partners, focuses on patient-identified priorities and improves patient outcomes. This research, conducted by multidisciplinary teams in partnership with stakeholders, aims to apply the knowledge generated to improve health care systems and practices. – msfhr.org - Michael Smith Foundation for Health Research

Patient engagement in clinical trail research is two-fold:

  1. Trial Participant – the human participant in the trial
  2. Patient Representative – developing and delivering the research question, ensuring: patient feasibility, outcomes that matter to patients

There are several touch points where a Patient Representative provides input as members of Scientific, Oversight and Support Committees. They are actively involved at key junctures of the CCTG Clinical Trial life cycle: Development, Review/Approval, Protocol and Consent Development, Accrual and Data Collection and at the time of Permanent Closure.

lay representative committee

Recognizing Volunteer Week, with sincere thanks to CCTG members, volunteers and supporters

Recognizing Volunteer Week, with sincere thanks to CCTG members, volunteers and supporters

Dear CCTG Members, Volunteers and Supporters,

On behalf of the Canadian Cancer Trials Group to all members and supporters, we extend our sincere gratitude to those who generously contribute their time, experience, expertise, and support to advance cancer research.

More >>
 
Patient Representative Darren Frew

Welcome to new Patient Representative Darren Frew

Please join us in welcoming Darren Frew who will be supporting the CCTG Gastrointestinal disease site committee. He resides in Burnaby BC and was treated successfully for colon cancer via surgery and chemotherapy in 2019/ 2020.  He is grateful the treatment went well and continues in the right direction.

More >>
 
New reassuring results for patients with breast cancer wanting to have a baby

New reassuring results for patients with breast cancer wanting to have a baby

Pausing endocrine treatment to attempt pregnancy can be considered - no additional risk of recurrences after 5 years. The MAC18 (POSITIVE) study, evaluating the pregnancy outcomes and safety of interrupting endocrine therapy for young women

More >>
 
CCTG SR.8 HARMONY sarcoma trial awarded CIHR funding

CCTG SR8 HARMONY sarcoma trial awarded CIHR funding

The CCTG SR.8 (HARMONY) clinical trial has been awarded almost 1.5 million through the CIHR spring Project Grant Program. A phase III study that addresses a significant unmet need in the treatment of high-risk soft-tissue sarcoma (STS).

More >>